Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions. Rani Therapeutics develops this technology for use across multiple therapeutic areas, including peptides, proteins, antibodies, and oligonucleotides. Its business is centered on advancing drug-delivery solutions that may support patients, physicians, and healthcare systems by making biologic administration more convenient. The company operates in the biotechnology and health care life sciences sectors, where oral delivery platforms are an important area of innovation.
Website2051 Ringwood Avenue
San Jose, CA, 95131
United States
What share of all stock conversation is about RANI?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% +0 |
Of the messages about RANI that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 100% 0 | 100% +5.1 | 86.77% +0.48 | ||
| Bearish | — | 0% 0 | 0% -5.1 | 13.23% -0.48 |
Of the messages about RANI that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 100% | 3.99% | ||
| Technical Analysis | — | — | 0% | 28.92% | ||
| Analysts | — | — | 0% | 33.23% | ||
| Controversies | — | — | 0% | 0% | ||
| Earnings | — | — | 0% | 0.04% | ||
| Macro | — | — | 0% | 33.82% |
Of the messages about RANI, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 75% | 86.67% | 8.15% | ||
| Newcomers | — | 25% | 13.33% | 91.85% |
SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming September conferences. 10th Annual Best Ideas Growth (BIG10) Conference hosted by Lake Street Capital MarketsDate: Thursday, September 10, 2026 Format: 1x1 MeetingsLocation: New York, NY H.C. Wainwright 28th Annual Global Investment C
Rani Therapeutics (NASDAQ:RANI) outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity. Chief Executive Officer Talat Imran described the clinic
Investors talking about RANI also mention